JPRN-UMIN000013788招募中未知
Relation between Efficacy of Adalimumab and Pharmacokinetics in Ulcerative colitis. - REAL Study
Department of Medicine, Shiga University of Medical Science0 个研究点目标入组 40 人开始时间: 2014年5月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 15years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Patients < 15 years of age (2) Pregnant or likely to be pregnant women (3) Patients with malignancy (4) Patients with severe infection (5) Patients who treated or dose escalated with steroid within 2 weeks. (6) Patients who treated with IFX within 8 weeks (7) Patients who treated or dose escalated with Azathioprine and 6-mercaptopurine within 8 weeks. (8) Patients who treated or dose escalated with tacrolimus within 4 weeks (9) Patients who treated with ciclosporin within 2 weeks (10) Patients who treated with cyteapheresis within 2 weeks (11) Patients not approving the study consent (12) Patients judged as inadequate at the discretion of physicians
研究者
相似试验
尚未招募
2 期
The effect of Adalimumab in the treatment of patients with chronic schizophreniaSchizophrenia.SchizophreniaIRCT20090117001556N126Tehran University of Medical Sciences50
招募中
2 期
Comparison of the effect of Adalimumab and Methotrexate in the treatment of psoriasisModerate to sever of psoriasis.Generalized pustular psoriasisL40.1IRCT20100102002954N26Shahroud University of Medical Sciences92
已完成
不适用
The Study for Efficacy and Safety of Adalimumab for Crohn's Disease with Loss of Response to InfliximabCrohn's Disease patient as following 1)or 2) 1)the patient who treated with IFX infusion of interval every 4-6 weeks. 2)the patient who could not keep to treat with IFX due to side effect or ineffectiveness.JPRN-UMIN000005761Kenji Watanabe50
已完成
4 期
Study of Combination Therapy of Adalimumab and an Immunomodulator for Crohn's Disease(Diamond study)s diseaseCrohn's diseaseJPRN-UMIN000005146Department of Internal Medicine, School of Medicine, Keio University200
已完成
2 期
Evaluating the effects of Adalimumab in patients with acute respiratory distress syndrome caused by COVID-19IRCT20151227025726N23Shahid Beheshti University of Medical Sciences60